For decades, the thyroid-stimulating hormone receptor (TSHR) has been a key target in understanding thyroid function and autoimmune thyroid diseases, including Graves’ disease. As drug development strategies continue to expand, approaches to targeting TSHR are no longer limited to traditional receptor blockade. From receptor antagonism and allosteric modulation to the direct clearance of pathogenic autoantibodies, new research approaches are reshaping the drug discovery landscape.
TSHR: A Key Driver of Autoimmune Thyroid Diseases
TSHR is a G protein-coupled receptor (GPCR) primarily expressed on the surface of thyroid follicular cells. Under physiological conditions, thyroid-stimulating hormone (TSH) binds to TSHR and regulates thyroid cell function mainly through the Gs-cAMP-PKA pathway. TSHR is also involved in other signaling processes, including Gq-PLC-PKC, MAPK, PI3K-AKT, and β-arrestin signaling.
In autoimmune thyroid diseases such as Graves’ disease, autoantibodies targeting TSHR can alter receptor activity. Among them, thyroid-stimulating antibodies (TSAb) activate receptor signaling, while blocking antibodies may inhibit the interaction between TSH and the receptor. This antibody-mediated regulation of TSHR is closely associated with disease development and progression, making TSHR an important focus of both drug discovery and functional research.
Three Emerging Strategies for Targeting TSHR
1. Receptor Blockade: Continued Exploration of Antibodies That Directly Modulate TSHR Activity
Direct TSHR blockade was among the earlier therapeutic strategies to attract attention. The underlying approach is to use antibodies that bind to the receptor to inhibit its activation by stimulating autoantibodies or interfere with interactions between the receptor and its ligands. Blocking the interaction between pathogenic autoantibodies and TSHR has long been an important strategy in drug development for Graves’ disease and thyroid eye disease.
Several antibody drug candidates have now advanced into clinical development.
· K1-70: An anti-TSHR monoclonal antibody currently being evaluated in a Phase II clinical study for thyroid eye disease.
· ETHY-001: A long-acting anti-TSHR monoclonal antibody developed by Ethyreal Bio. In October 2026, the company announced mechanistic proof-of-concept results from its first-in-human Phase I study and initiated patient cohorts for thyroid eye disease and Graves’ disease.
These programs demonstrate that directly inhibiting aberrant TSHR activation remains an important direction in drug development.
The focus of these strategies extends beyond whether an antibody can bind to TSHR. It also includes its actual effects on receptor function, such as whether it can inhibit ligand-induced signaling, whether it affects autoantibody-mediated receptor activation, and how its functional response varies across concentrations.
2. Allosteric Modulation: Expanding from Receptor-Binding Sites to Signal Regulation
Beyond directly competing for receptor-binding sites, allosteric modulation offers another approach to TSHR drug discovery. Allosteric modulators interact with non-orthosteric sites on the receptor, altering its conformation and signaling output to regulate receptor activity.
In November 2026, Septerna announced a noteworthy development in this field.
The company selectedSEP-204as a development candidate for the treatment of Graves’ disease and thyroid eye disease. SEP-204 is an oral small-molecule TSHR negative allosteric modulator (NAM).
Unlike conventional antagonists that compete with endogenous ligands for the orthosteric binding site, negative allosteric modulators bind to other sites on the receptor and regulate its activity by altering receptor function.
According to the company’s published preclinical results, SEP-204 demonstrated the following characteristics:
· Potent inhibitory activity against TSHR, with high selectivity.
· Restoration of normal T4 levels in an animal model of Graves’ disease.
· Reductions in thyroid enlargement and proptosis in preclinical models.
· Pharmacokinetic properties expected to support once-daily oral dosing.
Septerna plans to initiate a Phase I clinical trial in the first quarter of 2027. This development is particularly noteworthy because it expands TSHR drug discovery beyond conventional antibody therapies into the field of small-molecule GPCR modulation, further highlighting the development potential of small-molecule allosteric modulators.
This direction also highlights the need for TSHR functional assays to capture dynamic changes in receptor signaling, rather than focusing solely on whether a compound binds to the receptor.
3. Autoantibody Degradation: Shifting from Blocking Antibody Activity to Clearing Pathogenic Antibodies
Another emerging strategy does not directly block TSHR. Instead, it aims to reduce circulating levels of pathogenic autoantibodies. At the 2026 American Thyroid Association (ATA) Annual Meeting, Biohaven presented preclinical results forBHV-1440, a novel TRAP degrader designed to selectively clear anti-TSHR autoantibodies.
This approach uses a bifunctional molecule that simultaneously binds pathogenic anti-TSHR antibodies and the asialoglycoprotein receptor (ASGPR), promoting their uptake into liver cells and subsequent lysosomal degradation.
Preclinical results showed that BHV-1440 can:
· Bind both patient-derived anti-TSHR antibody M22 and ASGPR.
· Promote the uptake of M22 into primary human hepatocytes.
· Reduce circulating M22 levels in mouse models.
· Restore elevated T4 levels to near-baseline levels.
BHV-1440 remains in the preclinical stage of development.
Unlike conventional receptor blockers, BHV-1440 targets pathogenic autoantibodies rather than TSHR itself. It therefore represents a shift from intervention at the receptor level toward antibody clearance. At present, the publicly available data remain largely preclinical, and its clinical value and safety will need to be established in future studies.
What Do These New Strategies Mean for TSHR Functional Research?
Although the drug candidates described above use different molecular mechanisms, they address a common biological question: how do candidate drugs affect TSHR-mediated signal transduction?
Functional evaluation is therefore particularly important during the early stages of drug development.
Several aspects deserve attention:
Receptor Activation and Inhibition
Understanding the baseline receptor response to TSH stimulation and measuring the extent of inhibition of receptor-mediated signaling are essential to evaluating TSHR modulators.
Concentration-Dependent Responses
Dose-response analysis helps characterize the potency and functional effects of candidate compounds, including small-molecule negative allosteric modulators and receptor-blocking antibodies.
Antibody-Mediated Receptor Activation
Not all anti-TSHR antibodies have the same functional effects. Distinguishing stimulating antibodies from blocking antibodies requires functional assays, not binding assays alone.
Downstream Signaling Pathways
TSHR primarily signals through the Gs-cAMP-PKA pathway, but Gq-mediated signaling and downstream MAPK pathways also contribute to its broader biological responses. Studying these pathways can provide further insights into the receptor’s pharmacological profile.
For autoantibody-degrading drug candidates, TSHR-related functional assays may also help assess the receptor-stimulating activity of residual autoantibodies after treatment, complementing direct antibody quantification.
Genomeditech’s TSHR Research Tools
As TSHR-targeted drug development expands into different therapeutic mechanisms, reliable cell models are essential for characterizing receptor activity and evaluating candidate molecules.
Genomeditech offers a range of TSHR-related research tools, including:
· TSHR stable overexpression cell lines: For studying receptor expression, ligand interactions, and receptor-mediated biological responses.
· TSHR reporter assay cell lines: For monitoring TSHR-mediated signal transduction and evaluating the functional effects of receptor agonists and antagonists.
These models can be used for target functional validation, functional characterization, antibody screening, and compound evaluation.
Explore Genomeditech’s TSHR-related products:
https://en.genomeditech.com/v2/search?k=TSHR&utm_source=chatgpt.com
Looking Ahead
TSHR drug discovery is becoming increasingly diverse, encompassing direct receptor blockade, modulation of receptor activity through allosteric mechanisms, and the clearance of pathogenic autoantibodies. These strategies act on different stages of disease-related biological processes and bring more nuanced requirements for target characterization and in vitro evaluation.
As these programs continue to advance, functional research models capable of distinguishing receptor signal activation, inhibition, and antibody-mediated effects will remain important tools in TSHR research and the early evaluation of drug candidates.
References
1. Septerna. SEP-204 Selected as Development Candidate for Graves’ Disease and TED. November 4, 2026. https://ir.septerna.com/news-releases/news-release-details/septerna-announces-selection-sep-204-development-candidate
2. Septerna. Third Quarter 2026 Financial Results and Business Update. November 9, 2026. https://septerna.gcs-web.com/news-releases/news-release-details/septerna-highlights-business-progress-and-reports-third-quarter
3. Biohaven. Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 ATA Meeting. November 5, 2026. https://ir.biohaven.com/news-releases/news-release-details/biohaven-drives-new-research-graves-disease-phase-3-pivotal
4. Kleinau G, et al. Novel Insights on Thyroid-Stimulating Hormone Receptor Signal Transduction. Endocrine Reviews. 2013;34(5):691–724. https://doi.org/10.1210/er.2012-1072
5. Morshed SA, et al. Biased Signaling by Thyroid-Stimulating Hormone Receptor-Specific Antibodies Determines Thyrocyte Survival in Autoimmunity. Science Signaling. 2018;11(514). https://doi.org/10.1126/scisignal.aah4120
6. Xu S, et al. TSHR in thyroid cancer: bridging biological insights to targeted strategies. European Thyroid Journal. 2025;14(4). https://doi.org/10.1530/ETJ-24-0369
